首页 > 最新文献

中国癌症杂志最新文献

英文 中文
Immortalization of human fallopian tube epithelial cells 人输卵管上皮细胞的永生化
Q4 Medicine
China Oncology
Pub Date : 2014-11-19 DOI: 10.3969/J.ISSN.1007-3969.2013.04.00X
G. Wen, Zang Rong-yu, Wang Yan, Yang Li-na, Liu Yang, QI Zi-hao, Y. Sheng, Yang Gong
{"title":"Immortalization of human fallopian tube epithelial cells","authors":"G. Wen, Zang Rong-yu, Wang Yan, Yang Li-na, Liu Yang, QI Zi-hao, Y. Sheng, Yang Gong","doi":"10.3969/J.ISSN.1007-3969.2013.04.00X","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2013.04.00X","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"23 1","pages":"241-247"},"PeriodicalIF":0.0,"publicationDate":"2014-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
EGFR-TKI联合化疗治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效分析 EGFR-TKI联合化疗治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效分析
Q4 Medicine
China Oncology
Pub Date : 2014-11-13 DOI: 10.3969/J.ISSN.1007-3969.2013.06.011
李剑英, 吴晓敏, 何灵慧, 季从飞, 谭清和
背景与目的：对于（epidermal growth factor receptor tyrosine kinase inhibitor，EGFR—TKI）治疗失败的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者亟需探索新的治疗策略来延缓或克服EGFR-TKI的获得性耐药。本研究旨在比较对此类患者采用化疗联合EGFR—TKI与单化疗的疗效及不良反应。方法：符合入组标准的18例患者中，8例接受化疗联合EGFR—TKI（CE组），10例接受单化疗（c组），21d为1个周期，至少完成2个周期化疗的患者进行疗效及不良反应评价。结果：18例患者均可评价疗效，其中cE组客观反应率（objective response rate，ORR）为25％，C组ORR为10％，两组比较差异无统计学意义（P=0．832）；CE组疾病控制率（disease control rate，DCR）为87．5％，中位无进展生存期（progression free survival，PFS）为3．5个月，C组DCR为30％，中位PFS为2．4个月，两组比较差异有统计学意义（p=0．046，P=0．05）。CE组皮疹发生率高于C组（75％vs 10％），两组Ⅲ、Ⅳ度不良反应的差异均无统计学意义（P〉0．05）。结论：EGFR突变阳性的NSCLC患者，在EGFR—TKI耐药后继续使用EGFR-TKI并联用化疗可延缓疾病进展，是EGFR—TKI治疗失败的NSCLC患者的一项治疗策略。
背景与目的：对于（epidermal growth factor receptor tyrosine kinase inhibitor，EGFR—TKI）治疗失败的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者亟需探索新的治疗策略来延缓或克服EGFR-TKI的获得性耐药。本研究旨在比较对此类患者采用化疗联合EGFR—TKI与单化疗的疗效及不良反应。方法：符合入组标准的18例患者中，8例接受化疗联合EGFR—TKI（CE组），10例接受单化疗（c组），21d为1个周期，至少完成2个周期化疗的患者进行疗效及不良反应评价。结果：18例患者均可评价疗效，其中cE组客观反应率（objective response rate，ORR）为25％，C组ORR为10％，两组比较差异无统计学意义（P=0．832）；CE组疾病控制率（disease control rate，DCR）为87．5％，中位无进展生存期（progression free survival，PFS）为3．5个月，C组DCR为30％，中位PFS为2．4个月，两组比较差异有统计学意义（p=0．046，P=0．05）。CE组皮疹发生率高于C组（75％vs 10％），两组Ⅲ、Ⅳ度不良反应的差异均无统计学意义（P〉0．05）。结论：EGFR突变阳性的NSCLC患者，在EGFR—TKI耐药后继续使用EGFR-TKI并联用化疗可延缓疾病进展，是EGFR—TKI治疗失败的NSCLC患者的一项治疗策略。
{"title":"EGFR-TKI联合化疗治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效分析","authors":"李剑英, 吴晓敏, 何灵慧, 季从飞, 谭清和","doi":"10.3969/J.ISSN.1007-3969.2013.06.011","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2013.06.011","url":null,"abstract":"背景与目的：对于（epidermal growth factor receptor tyrosine kinase inhibitor，EGFR—TKI）治疗失败的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者亟需探索新的治疗策略来延缓或克服EGFR-TKI的获得性耐药。本研究旨在比较对此类患者采用化疗联合EGFR—TKI与单化疗的疗效及不良反应。方法：符合入组标准的18例患者中，8例接受化疗联合EGFR—TKI（CE组），10例接受单化疗（c组），21d为1个周期，至少完成2个周期化疗的患者进行疗效及不良反应评价。结果：18例患者均可评价疗效，其中cE组客观反应率（objective response rate，ORR）为25％，C组ORR为10％，两组比较差异无统计学意义（P=0．832）；CE组疾病控制率（disease control rate，DCR）为87．5％，中位无进展生存期（progression free survival，PFS）为3．5个月，C组DCR为30％，中位PFS为2．4个月，两组比较差异有统计学意义（p=0．046，P=0．05）。CE组皮疹发生率高于C组（75％vs 10％），两组Ⅲ、Ⅳ度不良反应的差异均无统计学意义（P〉0．05）。结论：EGFR突变阳性的NSCLC患者，在EGFR—TKI耐药后继续使用EGFR-TKI并联用化疗可延缓疾病进展，是EGFR—TKI治疗失败的NSCLC患者的一项治疗策略。","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"23 1","pages":"462-466"},"PeriodicalIF":0.0,"publicationDate":"2014-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast calcification plays a major role in breast cancer: form radiology assessment to chemical composition analysis 乳房钙化在乳腺癌中起着重要作用:从放射学评估到化学成分分析
Q4 Medicine
China Oncology
Pub Date : 2014-11-12 DOI: 10.3969/J.ISSN.1007-3969.2014.09.011
Huang Nai-si, W. Jiong
{"title":"Breast calcification plays a major role in breast cancer: form radiology assessment to chemical composition analysis","authors":"Huang Nai-si, W. Jiong","doi":"10.3969/J.ISSN.1007-3969.2014.09.011","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.09.011","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"1 1","pages":"707-712"},"PeriodicalIF":0.0,"publicationDate":"2014-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The research progress on double-hit lymphoma 双恶性淋巴瘤的研究进展
Q4 Medicine
China Oncology
Pub Date : 2014-11-12 DOI: 10.3969/J.ISSN.1007-3969.2014.10.005
G. Ye
{"title":"The research progress on double-hit lymphoma","authors":"G. Ye","doi":"10.3969/J.ISSN.1007-3969.2014.10.005","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.10.005","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"745-749"},"PeriodicalIF":0.0,"publicationDate":"2014-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of rs10993994 for the transcriptional activity of MSMB gene in prostate cancer cell lines rs10993994在前列腺癌细胞中MSMB基因转录活性的作用
Q4 Medicine
China Oncology
Pub Date : 2014-11-07 DOI: 10.3969/J.ISSN.1007-3969.2014.08.003
Sun Yao-fei, Z. Jie, F. Zu-jun, X. Zu-Quan, D. Qiang
{"title":"The role of rs10993994 for the transcriptional activity of MSMB gene in prostate cancer cell lines","authors":"Sun Yao-fei, Z. Jie, F. Zu-jun, X. Zu-Quan, D. Qiang","doi":"10.3969/J.ISSN.1007-3969.2014.08.003","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.08.003","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"575-580"},"PeriodicalIF":0.0,"publicationDate":"2014-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
结直肠癌患者血清中可溶性P-选择素和L-选择素水平及临床意义 结直肠癌患者血清中可溶性P-选择素和L-选择素水平及临床意义
Q4 Medicine
China Oncology
Pub Date : 2014-11-07 DOI: 10.3969/J.ISSN.1007-3969.2014.08.007
张梁, 罗桂飞, 元辉雄, 韦贵将
背景与目的：结直肠癌是常见的消化系统恶性肿瘤，严重威胁着人类的健康。虽然现代诊疗技术不断发展，但近年来结直肠癌的发病率和病死率仍呈逐年上升趋势，早期诊断和防治肝转移有助于提高结直肠癌患者的生存率，对改善其预后有重要意义。P-选择素和L-选择素是近年肿瘤研究领域倍受关注的分子，其表达量及介导的黏附作用的改变在肿瘤细胞转移中起着重要作用，但2者与结直肠癌发生及临床分期的关系鲜见报道。本研究旨在探讨结直肠癌患者手术前后血清中P-选择素和L-选择素水平高低与临床病理特征的相关性。方法：选择132例结直肠癌患者及与其性别年龄相匹配的100名健康体检者。采用酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）检测132例结直肠癌患者手术前后血清中P-选择素和L-选择素浓度，100名健康体检者为对照组，结合临床病理特征对P-选择素和L-选择素水平的变化进行分析。结果：结直肠癌患者术前血清P-选择素和L-选择素水平显著高于对照组（75.2±13.3vs 26.6±9.6，89.2±12.7vs 33.9±8.3，P〈0.05）；术后1周P-选择素和L-选择素水平较术前没有明显下降（63.8±11.1vs 75.2±13.3，71.5±10.9vs 89.2±12.7，P〉0.05）；而术后3个月则明显下降，与术前比较差异有统计学意义（34.8±10.4 vs 75.2±13.3，40.1±9.5vs 89.2±12.7，P〈0.01）；本组结直肠癌患者，临床分期越高，P-选择素和L-选择素水平越高，其水平与肿瘤浸润深度、Dukes分期、组织学分级和淋巴结转移相关，而与年龄、性别及肿瘤部位无明显相关（P〉0.05）；同时，同一结直肠癌患者血清中P-选择素和L-选择素的表达无显著相关（r=4.114， P〉0.05）。结论：血清中P-选择素和L-选择素的水平在一定程度上反映了结直肠癌的侵袭、浸润和淋巴结转移的程度，可作为预测结直肠癌发展及
背景与目的：结直肠癌是常见的消化系统恶性肿瘤，严重威胁着人类的健康。虽然现代诊疗技术不断发展，但近年来结直肠癌的发病率和病死率仍呈逐年上升趋势，早期诊断和防治肝转移有助于提高结直肠癌患者的生存率，对改善其预后有重要意义。P-选择素和L-选择素是近年肿瘤研究领域倍受关注的分子，其表达量及介导的黏附作用的改变在肿瘤细胞转移中起着重要作用，但2者与结直肠癌发生及临床分期的关系鲜见报道。本研究旨在探讨结直肠癌患者手术前后血清中P-选择素和L-选择素水平高低与临床病理特征的相关性。方法：选择132例结直肠癌患者及与其性别年龄相匹配的100名健康体检者。采用酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）检测132例结直肠癌患者手术前后血清中P-选择素和L-选择素浓度，100名健康体检者为对照组，结合临床病理特征对P-选择素和L-选择素水平的变化进行分析。结果：结直肠癌患者术前血清P-选择素和L-选择素水平显著高于对照组（75.2±13.3vs 26.6±9.6，89.2±12.7vs 33.9±8.3，P〈0.05）；术后1周P-选择素和L-选择素水平较术前没有明显下降（63.8±11.1vs 75.2±13.3，71.5±10.9vs 89.2±12.7，P〉0.05）；而术后3个月则明显下降，与术前比较差异有统计学意义（34.8±10.4 vs 75.2±13.3，40.1±9.5vs 89.2±12.7，P〈0.01）；本组结直肠癌患者，临床分期越高，P-选择素和L-选择素水平越高，其水平与肿瘤浸润深度、Dukes分期、组织学分级和淋巴结转移相关，而与年龄、性别及肿瘤部位无明显相关（P〉0.05）；同时，同一结直肠癌患者血清中P-选择素和L-选择素的表达无显著相关（r=4.114， P〉0.05）。结论：血清中P-选择素和L-选择素的水平在一定程度上反映了结直肠癌的侵袭、浸润和淋巴结转移的程度，可作为预测结直肠癌发展及
{"title":"结直肠癌患者血清中可溶性P-选择素和L-选择素水平及临床意义","authors":"张梁, 罗桂飞, 元辉雄, 韦贵将","doi":"10.3969/J.ISSN.1007-3969.2014.08.007","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.08.007","url":null,"abstract":"背景与目的：结直肠癌是常见的消化系统恶性肿瘤，严重威胁着人类的健康。虽然现代诊疗技术不断发展，但近年来结直肠癌的发病率和病死率仍呈逐年上升趋势，早期诊断和防治肝转移有助于提高结直肠癌患者的生存率，对改善其预后有重要意义。P-选择素和L-选择素是近年肿瘤研究领域倍受关注的分子，其表达量及介导的黏附作用的改变在肿瘤细胞转移中起着重要作用，但2者与结直肠癌发生及临床分期的关系鲜见报道。本研究旨在探讨结直肠癌患者手术前后血清中P-选择素和L-选择素水平高低与临床病理特征的相关性。方法：选择132例结直肠癌患者及与其性别年龄相匹配的100名健康体检者。采用酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）检测132例结直肠癌患者手术前后血清中P-选择素和L-选择素浓度，100名健康体检者为对照组，结合临床病理特征对P-选择素和L-选择素水平的变化进行分析。结果：结直肠癌患者术前血清P-选择素和L-选择素水平显著高于对照组（75.2±13.3vs 26.6±9.6，89.2±12.7vs 33.9±8.3，P〈0.05）；术后1周P-选择素和L-选择素水平较术前没有明显下降（63.8±11.1vs 75.2±13.3，71.5±10.9vs 89.2±12.7，P〉0.05）；而术后3个月则明显下降，与术前比较差异有统计学意义（34.8±10.4 vs 75.2±13.3，40.1±9.5vs 89.2±12.7，P〈0.01）；本组结直肠癌患者，临床分期越高，P-选择素和L-选择素水平越高，其水平与肿瘤浸润深度、Dukes分期、组织学分级和淋巴结转移相关，而与年龄、性别及肿瘤部位无明显相关（P〉0.05）；同时，同一结直肠癌患者血清中P-选择素和L-选择素的表达无显著相关（r=4.114， P〉0.05）。结论：血清中P-选择素和L-选择素的水平在一定程度上反映了结直肠癌的侵袭、浸润和淋巴结转移的程度，可作为预测结直肠癌发展及","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"275 1","pages":"599-603"},"PeriodicalIF":0.0,"publicationDate":"2014-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib 间歇性给药valacyclovir可有效预防用硼替佐米治疗的多发性骨髓瘤患者的带状疱疹事件
Q4 Medicine
China Oncology
Pub Date : 2014-07-29 DOI: 10.3969/J.ISSN.1007-3969.2014.07.009
Yao Yi-yun, T. Yong, Zhuang Yan, W. Lei, Zou Li-fang, Z. Qi
{"title":"Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib","authors":"Yao Yi-yun, T. Yong, Zhuang Yan, W. Lei, Zou Li-fang, Z. Qi","doi":"10.3969/J.ISSN.1007-3969.2014.07.009","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.07.009","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"525-528"},"PeriodicalIF":0.0,"publicationDate":"2014-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparison of set-up errors detected by EPID and CBCT using two different immobilization techniques for patients with nasopharygeal carcinoma 鼻咽癌患者两种不同固定技术下EPID和CBCT设置误差检测的比较
Q4 Medicine
China Oncology
Pub Date : 2014-07-29 DOI: 10.3969/J.ISSN.1007-3969.2014.07.011
Lu Wei, Xu Ting-ting, Xu Qing, Ying Hong-mei, Chao-su Hu
{"title":"Comparison of set-up errors detected by EPID and CBCT using two different immobilization techniques for patients with nasopharygeal carcinoma","authors":"Lu Wei, Xu Ting-ting, Xu Qing, Ying Hong-mei, Chao-su Hu","doi":"10.3969/J.ISSN.1007-3969.2014.07.011","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.07.011","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"535-539"},"PeriodicalIF":0.0,"publicationDate":"2014-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
MRI in the differential diagnosis of breast ductal cancer in situ MRI在乳腺导管原位癌鉴别诊断中的价值
Q4 Medicine
China Oncology
Pub Date : 2014-07-29 DOI: 10.3969/J.ISSN.1007-3969.2014.06.011
Y. Chao, G. Yajia, Peng Weijun, Mao Jian, Ji Ting-ting
{"title":"MRI in the differential diagnosis of breast ductal cancer in situ","authors":"Y. Chao, G. Yajia, Peng Weijun, Mao Jian, Ji Ting-ting","doi":"10.3969/J.ISSN.1007-3969.2014.06.011","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.06.011","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"463-468"},"PeriodicalIF":0.0,"publicationDate":"2014-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
癌相关成纤维细胞通过Gro-α激活NF-кB核转位和VEGF表达促进卵巢癌的生长 癌相关成纤维细胞通过Gro-α激活NF-кB核转位和VEGF表达促进卵巢癌的生长
Q4 Medicine
China Oncology
Pub Date : 2014-05-26 DOI: 10.3969/J.ISSN.1007-3969.2014.05.001
任春霞, 徐娜, 宋亚琴, 赵敏, 陈亚萍, 吕蓓, 杨恭
背景与目的：卵巢癌相关成纤维细胞（cancer-associated fibroblasts，CAF）促进上皮肿瘤的发生，其分泌的趋化因子即生长调节致癌基因α（growth-regulated oncogene alpha，Gro-α）蛋白在肿瘤间质微环境中促进上皮卵巢癌的发生，但其作用机制并不清楚。本研究拟测定Gro-α蛋白是否通过激活间质成纤维细胞中NF-кB核转位和VEGF表达，促进卵巢癌的生长。方法：本研究采用ELISA法测定了两株卵巢癌CAF和两株正常卵巢组织成纤维细胞（normal fibroblasts，NF）条件培养基（conditioned medium，CM）中Gro-α的表达；用CAF-CM或Gro-α分别处理NF，并以NF-кB抑制剂处理作为对照；用蛋白质印迹法（Western blot）测定样品处理前后NF-кB和血管内皮细胞生长因子（vascular endothelial growth factor，VEGF）等分子的变化；然后用CAF或NF分别与卵巢癌细胞系OVCA429混合接种BALB/c裸小鼠，或在有、无NF-кB抑制剂PS1145处理的NF中，用CAF-CM或Gro-α处理后，分别与OVCA429混合接种动物，观察和比较动物移植瘤生长及移植瘤组织中微血管形成情况。结果：Gro-α在CAF中比在NF中高5-6倍；与对照组相比，用CAF条件培养基或Gro-α处理的NF中NF-кB p65的核转位升高，且VEGF上升，但血管生成抑制因子-血小板反应蛋白1下降；用NF-кB抑制剂同时处理NF，可以逆转其VEGF和TSP-1的表达水平；动物试验结果发现CAF要比NF更易促进肿瘤生长，而CAF-CM或Gro-α处理的NF细胞可以促进动物移植瘤的快速增长和移植瘤组织中微血管的生成，但用NF-кB抑制剂处理的NF则抑制肿瘤生长和血管形成能力。结论：卵巢癌CAF在肿瘤微环境中通过自分泌Gro-α，激活NF-кB核转位和VEGF表达，促进卵巢癌组织血管增生和肿瘤的生长。
背景与目的：卵巢癌相关成纤维细胞（cancer-associated fibroblasts，CAF）促进上皮肿瘤的发生，其分泌的趋化因子即生长调节致癌基因α（growth-regulated oncogene alpha，Gro-α）蛋白在肿瘤间质微环境中促进上皮卵巢癌的发生，但其作用机制并不清楚。本研究拟测定Gro-α蛋白是否通过激活间质成纤维细胞中NF-кB核转位和VEGF表达，促进卵巢癌的生长。方法：本研究采用ELISA法测定了两株卵巢癌CAF和两株正常卵巢组织成纤维细胞（normal fibroblasts，NF）条件培养基（conditioned medium，CM）中Gro-α的表达；用CAF-CM或Gro-α分别处理NF，并以NF-кB抑制剂处理作为对照；用蛋白质印迹法（Western blot）测定样品处理前后NF-кB和血管内皮细胞生长因子（vascular endothelial growth factor，VEGF）等分子的变化；然后用CAF或NF分别与卵巢癌细胞系OVCA429混合接种BALB/c裸小鼠，或在有、无NF-кB抑制剂PS1145处理的NF中，用CAF-CM或Gro-α处理后，分别与OVCA429混合接种动物，观察和比较动物移植瘤生长及移植瘤组织中微血管形成情况。结果：Gro-α在CAF中比在NF中高5-6倍；与对照组相比，用CAF条件培养基或Gro-α处理的NF中NF-кB p65的核转位升高，且VEGF上升，但血管生成抑制因子-血小板反应蛋白1下降；用NF-кB抑制剂同时处理NF，可以逆转其VEGF和TSP-1的表达水平；动物试验结果发现CAF要比NF更易促进肿瘤生长，而CAF-CM或Gro-α处理的NF细胞可以促进动物移植瘤的快速增长和移植瘤组织中微血管的生成，但用NF-кB抑制剂处理的NF则抑制肿瘤生长和血管形成能力。结论：卵巢癌CAF在肿瘤微环境中通过自分泌Gro-α，激活NF-кB核转位和VEGF表达，促进卵巢癌组织血管增生和肿瘤的生长。
{"title":"癌相关成纤维细胞通过Gro-α激活NF-кB核转位和VEGF表达促进卵巢癌的生长","authors":"任春霞, 徐娜, 宋亚琴, 赵敏, 陈亚萍, 吕蓓, 杨恭","doi":"10.3969/J.ISSN.1007-3969.2014.05.001","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.05.001","url":null,"abstract":"背景与目的：卵巢癌相关成纤维细胞（cancer-associated fibroblasts，CAF）促进上皮肿瘤的发生，其分泌的趋化因子即生长调节致癌基因α（growth-regulated oncogene alpha，Gro-α）蛋白在肿瘤间质微环境中促进上皮卵巢癌的发生，但其作用机制并不清楚。本研究拟测定Gro-α蛋白是否通过激活间质成纤维细胞中NF-кB核转位和VEGF表达，促进卵巢癌的生长。方法：本研究采用ELISA法测定了两株卵巢癌CAF和两株正常卵巢组织成纤维细胞（normal fibroblasts，NF）条件培养基（conditioned medium，CM）中Gro-α的表达；用CAF-CM或Gro-α分别处理NF，并以NF-кB抑制剂处理作为对照；用蛋白质印迹法（Western blot）测定样品处理前后NF-кB和血管内皮细胞生长因子（vascular endothelial growth factor，VEGF）等分子的变化；然后用CAF或NF分别与卵巢癌细胞系OVCA429混合接种BALB/c裸小鼠，或在有、无NF-кB抑制剂PS1145处理的NF中，用CAF-CM或Gro-α处理后，分别与OVCA429混合接种动物，观察和比较动物移植瘤生长及移植瘤组织中微血管形成情况。结果：Gro-α在CAF中比在NF中高5-6倍；与对照组相比，用CAF条件培养基或Gro-α处理的NF中NF-кB p65的核转位升高，且VEGF上升，但血管生成抑制因子-血小板反应蛋白1下降；用NF-кB抑制剂同时处理NF，可以逆转其VEGF和TSP-1的表达水平；动物试验结果发现CAF要比NF更易促进肿瘤生长，而CAF-CM或Gro-α处理的NF细胞可以促进动物移植瘤的快速增长和移植瘤组织中微血管的生成，但用NF-кB抑制剂处理的NF则抑制肿瘤生长和血管形成能力。结论：卵巢癌CAF在肿瘤微环境中通过自分泌Gro-α，激活NF-кB核转位和VEGF表达，促进卵巢癌组织血管增生和肿瘤的生长。","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"321-328"},"PeriodicalIF":0.0,"publicationDate":"2014-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
中国癌症杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1